About this book:

Founded in 1985 as Innovative Medical Technologies by microbiologist Dr. Raymond Kralovic, STERIS emerged to solve a critical healthcare challenge: the safe reprocessing of delicate, heat-sensitive endoscopic instruments. Under the leadership of Bill Sanford, who joined in 1987 and renamed the company STERIS Corporation, the firm launched the revolutionary STERIS System 1 in 1988—a rapid, low-temperature liquid chemical sterilization system that transformed surgical workflows and established a recurring revenue model through proprietary consumables. This foundational innovation, coupled with a culture centered on "Customers First" and continuous innovation, fueled rapid growth, culminating in a successful 1994 IPO on NASDAQ that provided capital for aggressive expansion.

The post-IPO era was defined by strategic diversification, most notably the transformative 1996 acquisition of Amsco International, which instantly propelled STERIS into traditional steam sterilization and surgical equipment, creating a comprehensive infection prevention portfolio. Subsequent decades saw the company navigate regulatory complexities, economic downturns, and the 2008 financial crisis through a resilient business model balanced between capital equipment and stable service/consumable revenue. Leadership transitions maintained strategic continuity, driving global expansion, entry into the life sciences and industrial sterilization markets, and a pivot toward digital solutions like instrument tracking and data analytics. The 2021 acquisition of Cantel Medical further solidified its dominance in endoscopy and opened the dental market.

STERIS’s ascent to the S&P 500 reflects decades of disciplined execution, consistent financial performance, and essential market positioning. Today, headquartered in Dublin with operational roots in Mentor, Ohio, the company operates a vast global network spanning healthcare and life sciences, offering integrated solutions from vaporized hydrogen peroxide sterilizers and robotic instrument reprocessing to contract sterilization services for pharmaceutical manufacturers. Its enduring legacy is built on a relentless commitment to patient safety, quality compliance, and R&D investment. Looking forward, STERIS aims to sustain growth by leveraging artificial intelligence, expanding in emerging markets, advancing sustainable technologies, and deepening its role as an indispensable partner in global health infrastructure.

What You'll Find Inside:

• STERIS's evolution from a 1985 startup with the revolutionary System 1 low-temperature sterilizer to a diversified S&P 500 global leader in infection prevention and procedural solutions.
• The critical role of strategic acquisitions—especially Amsco International (1996) and Cantel Medical (2021)—in expanding STERIS's portfolio from niche liquid sterilization to comprehensive steam, surgical, endoscopy, and life sciences offerings.
• How STERIS built a resilient 'razor-and-blade' business model combining capital equipment sales with recurring revenue from proprietary consumables, services, and contract sterilization that weathered economic downturns.
• The company's continuous innovation across sterilization modalities (liquid chemical, steam, VHP, EtO, radiation), digital integration (instrument tracking, data analytics, AI), and expansion into pharmaceutical/medical device manufacturing support.
• STERIS's enduring commitment to quality, regulatory compliance, and a values-driven culture ('Customers First – Always,' 'People – the foundation') that enabled global expansion and sustained leadership in patient safety.

Who's It For:

This book is ideal for business leaders and entrepreneurs seeking lessons in strategic growth, M&A integration, and building resilient recurring-revenue models in regulated industries. Healthcare professionals and medical device executives will gain deep insight into the evolution of sterilization technologies and infection prevention standards. Investors and analysts will appreciate the detailed case study of a company's path to S&P 500 inclusion through innovation, diversification, and financial discipline. Anyone interested in the intersection of medical innovation, corporate strategy, and global health impact will find this corporate history both instructive and inspiring.